{"filing":{"accession_number":"0001493152-26-039148","cik":"0002029039","ticker":"NSRX","company_name":"Nasus Pharma Ltd","form":"6-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2029039/000149315226039148/form6-k.htm"},"events":[{"id":28442,"run_id":26019,"accession_number":"0001493152-26-039148","anchor_item_number":"EX-99.1","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces the departure of Chief Financial Officer Eyal Rubin, who \"will be leaving the Company to pursue a new opportunity outside of the life science industry\" effective September 18, 2026. Simultaneously, Oren Elmaliach, the Director of Finance, has been appointed Interim Chief Financial Officer. The primary disclosed action is Rubin's departure from a named executive officer role, making this an exec_departure event. The CFO transition at a clinical-stage pharmaceutical company is material to investors assessing management continuity and financial oversight.","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-08-19","form":"6-K","submitted_at":null,"items":[{"id":30390,"accession_number":"0001493152-26-039148","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the departure of Chief Financial Officer Eyal Rubin, who \"will be leaving the Company to pursue a new opportunity outside of the life science industry\" effective September 18, 2026. Simultaneously, Oren Elmaliach, the Director of Finance, has been appointed Interim Chief Financial Officer. The primary disclosed action is Rubin's departure from a named executive officer role, making this an exec_departure event. The CFO transition at a clinical-stage pharmaceutical company is material to investors assessing management continuity and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:21:38.968800+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30390,"accession_number":"0001493152-26-039148","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the departure of Chief Financial Officer Eyal Rubin, who \"will be leaving the Company to pursue a new opportunity outside of the life science industry\" effective September 18, 2026. Simultaneously, Oren Elmaliach, the Director of Finance, has been appointed Interim Chief Financial Officer. The primary disclosed action is Rubin's departure from a named executive officer role, making this an exec_departure event. The CFO transition at a clinical-stage pharmaceutical company is material to investors assessing management continuity and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-19T13:21:38.968800+00:00","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-08-19"}]}